HIGRT May Help Manage Metastatic RCC
Hypofractionated image-guided radiation could delay use of systemic therapy, which can be quite toxic.
Hypofractionated image-guided radiation could delay use of systemic therapy, which can be quite toxic.
Targeted prostate biopsies using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may enable surgeons to select candidates for focal therapy of early-stage prostate cancer, according to researchers.
Magnetic resonance imaging (MRI) may be superior to computed tomography for radiographic surveillance following laparoscopic renal cryoablation of renal masses, researchers reported at the World Congress of Endourology in Chicago.
SAN FRANCISCO—For the first time, clinicians may have an imaging tool that can help distinguish clear cell renal cell carcinoma (RCC) from other kinds of renal masses.
The FDA has approved Cysview (hexaminolevulinate HCl), an optical imaging agent indicated for use in the cystoscopic detection of non-muscle-invasive papillary bladder cancer in patients suspected or known to have lesions on the basis of prior cystoscopy.
ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan).
In an interview with Renal & Urology News, Robert D. Kreisman, JD, of Kreisman Law Offices in Chicago, shares some insights on legal issues related to imaging tests.
This article is the second in a two-part series on the expanding use of imaging studies.
Toronto-based hybridyne Imaging Technologies has received FDA clearance for ProxiScan, a high-resolution gamma camera for detecting cancer and other abnormalities.
This article is the first in a two-part series examining the expanding use of diagnostic imaging in urology.